Diagnostic procedures in the follow-up of patients affected by men type 2

Ettore Seregni, Federica Pallotti, Franco Mattavelli, Leonardo Ferrari, Antonia Martinetti, Gianluca Aliberti, Carlo Villano, Maria Rita Castellani, Emilio Bombardieri

Research output: Contribution to journalArticle

Abstract

Multiple endocrine neoplasia type 2 (MEN 2) is an inherited disease caused by germline mutations in the RET proto-oncogene. The most distinctive MEN 2 variants are MEN 2A, MEN 2B and familial medullary thyroid cancer (FMTC). The hallmark of these syndromes is the development of medullary thyroid carcinoma (MTC), which occurs in almost all patients with MEN 2 syndromes. Other endocrinopathies are variably expressed. Pheochromocytoma and hyperparathyroidism occur in patients with MEN 2A with a frequency of about 50% and 30%, respectlvely. In this paper we summarize the most relevant diagnostic methods to detect and monitor MTC, pheochromocytoma and hyperparathyroidism.

Original languageEnglish
Pages (from-to)563-565
Number of pages3
JournalTumori
Volume89
Issue number5
Publication statusPublished - Sep 2003

Fingerprint

Multiple Endocrine Neoplasia Type 2a
Hyperparathyroidism
Pheochromocytoma
Multiple Endocrine Neoplasia Type 2b
Multiple Endocrine Neoplasia
Proto-Oncogenes
Germ-Line Mutation

Keywords

  • Hyperparathyroidism
  • Medullary thyroid carcinoma (MTC)
  • MEN 2 syndromes
  • Pheochromocytoma

ASJC Scopus subject areas

  • Cancer Research

Cite this

Seregni, E., Pallotti, F., Mattavelli, F., Ferrari, L., Martinetti, A., Aliberti, G., ... Bombardieri, E. (2003). Diagnostic procedures in the follow-up of patients affected by men type 2. Tumori, 89(5), 563-565.

Diagnostic procedures in the follow-up of patients affected by men type 2. / Seregni, Ettore; Pallotti, Federica; Mattavelli, Franco; Ferrari, Leonardo; Martinetti, Antonia; Aliberti, Gianluca; Villano, Carlo; Castellani, Maria Rita; Bombardieri, Emilio.

In: Tumori, Vol. 89, No. 5, 09.2003, p. 563-565.

Research output: Contribution to journalArticle

Seregni, E, Pallotti, F, Mattavelli, F, Ferrari, L, Martinetti, A, Aliberti, G, Villano, C, Castellani, MR & Bombardieri, E 2003, 'Diagnostic procedures in the follow-up of patients affected by men type 2', Tumori, vol. 89, no. 5, pp. 563-565.
Seregni E, Pallotti F, Mattavelli F, Ferrari L, Martinetti A, Aliberti G et al. Diagnostic procedures in the follow-up of patients affected by men type 2. Tumori. 2003 Sep;89(5):563-565.
Seregni, Ettore ; Pallotti, Federica ; Mattavelli, Franco ; Ferrari, Leonardo ; Martinetti, Antonia ; Aliberti, Gianluca ; Villano, Carlo ; Castellani, Maria Rita ; Bombardieri, Emilio. / Diagnostic procedures in the follow-up of patients affected by men type 2. In: Tumori. 2003 ; Vol. 89, No. 5. pp. 563-565.
@article{66348911561d492caa4c6e4dc4949ba3,
title = "Diagnostic procedures in the follow-up of patients affected by men type 2",
abstract = "Multiple endocrine neoplasia type 2 (MEN 2) is an inherited disease caused by germline mutations in the RET proto-oncogene. The most distinctive MEN 2 variants are MEN 2A, MEN 2B and familial medullary thyroid cancer (FMTC). The hallmark of these syndromes is the development of medullary thyroid carcinoma (MTC), which occurs in almost all patients with MEN 2 syndromes. Other endocrinopathies are variably expressed. Pheochromocytoma and hyperparathyroidism occur in patients with MEN 2A with a frequency of about 50{\%} and 30{\%}, respectlvely. In this paper we summarize the most relevant diagnostic methods to detect and monitor MTC, pheochromocytoma and hyperparathyroidism.",
keywords = "Hyperparathyroidism, Medullary thyroid carcinoma (MTC), MEN 2 syndromes, Pheochromocytoma",
author = "Ettore Seregni and Federica Pallotti and Franco Mattavelli and Leonardo Ferrari and Antonia Martinetti and Gianluca Aliberti and Carlo Villano and Castellani, {Maria Rita} and Emilio Bombardieri",
year = "2003",
month = "9",
language = "English",
volume = "89",
pages = "563--565",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Diagnostic procedures in the follow-up of patients affected by men type 2

AU - Seregni, Ettore

AU - Pallotti, Federica

AU - Mattavelli, Franco

AU - Ferrari, Leonardo

AU - Martinetti, Antonia

AU - Aliberti, Gianluca

AU - Villano, Carlo

AU - Castellani, Maria Rita

AU - Bombardieri, Emilio

PY - 2003/9

Y1 - 2003/9

N2 - Multiple endocrine neoplasia type 2 (MEN 2) is an inherited disease caused by germline mutations in the RET proto-oncogene. The most distinctive MEN 2 variants are MEN 2A, MEN 2B and familial medullary thyroid cancer (FMTC). The hallmark of these syndromes is the development of medullary thyroid carcinoma (MTC), which occurs in almost all patients with MEN 2 syndromes. Other endocrinopathies are variably expressed. Pheochromocytoma and hyperparathyroidism occur in patients with MEN 2A with a frequency of about 50% and 30%, respectlvely. In this paper we summarize the most relevant diagnostic methods to detect and monitor MTC, pheochromocytoma and hyperparathyroidism.

AB - Multiple endocrine neoplasia type 2 (MEN 2) is an inherited disease caused by germline mutations in the RET proto-oncogene. The most distinctive MEN 2 variants are MEN 2A, MEN 2B and familial medullary thyroid cancer (FMTC). The hallmark of these syndromes is the development of medullary thyroid carcinoma (MTC), which occurs in almost all patients with MEN 2 syndromes. Other endocrinopathies are variably expressed. Pheochromocytoma and hyperparathyroidism occur in patients with MEN 2A with a frequency of about 50% and 30%, respectlvely. In this paper we summarize the most relevant diagnostic methods to detect and monitor MTC, pheochromocytoma and hyperparathyroidism.

KW - Hyperparathyroidism

KW - Medullary thyroid carcinoma (MTC)

KW - MEN 2 syndromes

KW - Pheochromocytoma

UR - http://www.scopus.com/inward/record.url?scp=0346564118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346564118&partnerID=8YFLogxK

M3 - Article

C2 - 14870788

AN - SCOPUS:0346564118

VL - 89

SP - 563

EP - 565

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -